Daryl J. Hoban

Q: What Schools Are Affiliated With Daryl J. Hoban

Daryl J. Hoban is affiliated with the following schools: University of Manitoba, University of Toronto

Daryl J. Hoban's AcademicInfluence.com Rankings

Daryl J. Hoban

Medical

#3044

World Rank

#3495

Historical Rank

Pharmacology

#357

World Rank

#408

Historical Rank

medical Degrees

Daryl J. Hoban

Philosophy

#8778

World Rank

#12222

Historical Rank

Logic

#5796

World Rank

#7235

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Daryl J. Hoban's Degrees

PhD Pharmacology University of California, San Francisco
Doctorate Medicine University of California, San Francisco

Why Is Daryl J. Hoban Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Daryl J. Hoban's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comparative Review of the Carbapenems (2012) (468)
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. (2001) (393)
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination (2013) (351)
Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). (2006) (311)
A Critical Review of the Fluoroquinolones (2002) (298)
Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006 (2008) (281)
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli (2013) (262)
Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 (2009) (258)
Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations (2017) (244)
Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System (2000) (240)
Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). (2005) (235)
Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study (2006) (194)
A Canadian National Surveillance Study of Urinary Tract Isolates from Outpatients: Comparison of the Activities of Trimethoprim-Sulfamethoxazole, Ampicillin, Mecillinam, Nitrofurantoin, and Ciprofloxacin (2000) (179)
Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. (2004) (177)
New Lipoglycopeptides (2010) (174)
Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). (2011) (171)
Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System (1999) (171)
The glycylcyclines: a comparative review with the tetracyclines. (2004) (170)
A critical review of the fluoroquinolones: focus on respiratory infections. (2002) (170)
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent (2016) (169)
Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008) (2010) (166)
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). (2005) (166)
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin (2012) (161)
Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 (2003) (160)
The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. (2002) (160)
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. (2011) (148)
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). (2003) (147)
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. (2013) (147)
The Glycylcyclines (2004) (143)
Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens (2015) (132)
Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. (2011) (131)
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. (2009) (129)
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. (2013) (127)
Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. (1987) (126)
Antimicrobial Resistance in Urinary Tract Pathogens in Canada from 2007 to 2009: CANWARD Surveillance Study (2011) (123)
Review of macrolides and ketolides: focus on respiratory tract infections. (2001) (118)
The Postantibiotic Effect: A Review of in Vitro and in Vivo Data (1991) (115)
Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014. (2016) (114)
The new fluoroquinolones: A critical review. (1999) (113)
Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 (2003) (109)
Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). (2003) (108)
Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus Study Group (1994) (107)
Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. (2012) (106)
Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. (2013) (106)
Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). (2010) (104)
In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species (1997) (99)
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. (1993) (98)
Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. (2016) (96)
Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. (2011) (95)
Effect of iron on conversion of acetic acid to methane during methanogenic fermentations. (1979) (95)
Global Incidence of Carbapenemase-Producing Escherichia coli ST131 (2014) (94)
Review of Macrolides and Ketolides (2012) (93)
Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. (2011) (93)
Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART) (2010) (92)
Macrolide-Resistant Streptococcus pneumoniae in Canada during 1998–1999: Prevalence ofmef(A) and erm(B) and Susceptibilities to Ketolides (2001) (91)
In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012 (2014) (88)
Ertapenem: review of a new carbapenem (2005) (86)
Tigecycline: a novel glycylcycline antibiotic (2006) (85)
Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae: Results of a Canadian National Surveillance Study (2000) (85)
Prevalence of Antimicrobial Resistance among Clinical Isolates of Bacteroides fragilis Group in Canada in 2010-2011: CANWARD Surveillance Study (2011) (84)
Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases (2011) (82)
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004) (2005) (80)
Rapid Identification of Bacteria from Positive Blood Cultures by Fluorescence-Based PCR–Single-Strand Conformation Polymorphism Analysis of the 16S rRNA Gene (2000) (80)
Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. (2009) (78)
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. (2003) (77)
In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates (2009) (75)
Stretching the mutant prevention concentration (MPC) beyond its limits. (2003) (74)
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. (2002) (74)
The ketolides: a critical review. (2002) (74)
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. (2008) (73)
Candidemia in a Canadian tertiary care hospital from 1976 to 1996. (1997) (71)
In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008 (2009) (70)
In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. (2009) (70)
In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002 (2004) (68)
Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) (2010) (67)
Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. (2011) (67)
Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. (2011) (66)
In Vitro Susceptibilities of Candida andCryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients (1999) (65)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study) (2011) (65)
Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. (2008) (65)
In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. (2001) (64)
Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel β-Lactamases: a Snapshot of Extended-Spectrum β-Lactamases throughout the World (2012) (63)
AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity (2009) (63)
Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. (2004) (63)
Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010 (2012) (62)
Antimicrobial Resistance in Respiratory Tract Streptococcus pneumoniae Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002 (2003) (61)
In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. (2005) (59)
Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. (2011) (59)
In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). (2005) (58)
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). (2007) (57)
Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013 (2015) (57)
Molecular Characterization of Increasing Fluoroquinolone Resistance in Streptococcus pneumoniae Isolates in Canada, 1997 to 2005 (2006) (57)
A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. (2004) (57)
Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13. (2015) (56)
Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates (2011) (55)
Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). (2012) (54)
Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. (2007) (54)
Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada. (2013) (53)
Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections (2008) (53)
In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis (2007) (52)
Faropenem: review of a new oral penem (2007) (52)
Bacteremia in a long term care facility. (1994) (52)
Mutant Prevention Concentrations for Single-Step Fluoroquinolone-Resistant Mutants of Wild-Type, Efflux-Positive, or ParC or GyrA Mutation-Containing Streptococcus pneumoniae Isolates (2004) (51)
Antimicrobial susceptibility of Gram‐negative ESKAPE pathogens isolated from hospitalized patients with intra‐abdominal and urinary tract infections in Asia‐Pacific countries: SMART 2013‐2015 (2017) (51)
In Vitro Activity of Fosfomycin against Escherichia coli Isolated from Patients with Urinary Tract Infections in Canada as Part of the CANWARD Surveillance Study (2013) (50)
Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units. (2009) (50)
Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro. (1994) (50)
Penicillin-Binding Protein 1A, 2B, and 2X Alterations in Canadian Isolates of Penicillin-Resistant Streptococcus pneumoniae (2002) (49)
Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012 (2014) (49)
Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015 (2017) (48)
Antimicrobial activity of subinhibitory concentrations of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect. (1991) (48)
Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. (2002) (48)
In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa (1996) (48)
Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study. (2011) (47)
In Vitro Activity of Ceftaroline against Gram-Positive and Gram-Negative Pathogens Isolated from Patients in Canadian Hospitals in 2009 (2011) (47)
Nitrofurantoin Is Active against Vancomycin-Resistant Enterococci (2001) (47)
Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America. (2009) (47)
Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. (2003) (46)
Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations (2002) (46)
A Review of New Fluoroquinolones (2006) (46)
Survey of Bacteroides fragilis group susceptibility patterns in Canada (1992) (46)
Influence of Human Serum on Antifungal Pharmacodynamics with Candida albicans (2001) (46)
Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. (2013) (45)
Etiology, Extended-spectrum &bgr;-lactamase Rates and Antimicrobial Susceptibility of Gram-negative Bacilli Causing Intra-abdominal Infections in Patients in General Pediatric and Pediatric Intensive Care Units—Global Data From The Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010 (2013) (45)
Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones (1995) (45)
Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998. (2000) (43)
Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008 (2011) (43)
Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents. (2001) (43)
The Ketolides (2012) (43)
Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program. (2014) (42)
Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. (2010) (42)
Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15. (2018) (41)
Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study. (2010) (41)
In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. (1999) (40)
Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. (2002) (40)
Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. (2013) (38)
Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. (2003) (38)
Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units (2008) (38)
Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. (2017) (38)
Epidemiology of Vancomycin-Resistant Enterococci in Canadian Hospitals (CANWARD Study, 2007 to 2013) (2015) (38)
Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014 (2016) (38)
In Vitro Activity of Ceftaroline-Avibactam against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals from 2010 to 2012: Results from the CANWARD Surveillance Study (2013) (37)
In Vitro Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012 (2013) (37)
Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000. (2005) (37)
Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. (2013) (37)
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program (2015) (37)
Bacterial antigen detection in cerebrospinal fluid of patients with meningitis. (1985) (37)
Microbiological profile of a new topical antibacterial: retapamulin ointment 1% (2009) (37)
A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniaeIsolates from across Europe, North America, and South America (2000) (36)
Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. (2014) (36)
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. (2006) (36)
Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). (2008) (36)
Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322 (2013) (35)
Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13. (2015) (35)
Subinhibitory antimicrobial concentrations: A review of in vitro and in vivo data. (1992) (34)
In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. (2011) (34)
Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). (2004) (34)
Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia (2016) (34)
Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. (2013) (34)
Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. (1994) (34)
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. (2013) (33)
In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. (2011) (33)
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. (2001) (33)
Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae: Results of a Canadian National Surveillance Study (1999) (32)
Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae (2003) (32)
Molecular epidemiology of urinary tract isolates of vancomycin-resistant Enterococcus faecium from North America. (2006) (32)
42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study. (2019) (31)
Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. (2005) (31)
Effect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli (1992) (31)
Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011). (2014) (31)
In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. (1993) (31)
Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010. (2013) (31)
Molecular Epidemiology of Penicillin-Resistant and Ciprofloxacin-Resistant Streptococcus pneumoniae in Canada (2003) (30)
Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. (2014) (30)
Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae. (2000) (29)
Antimicrobial susceptibilities of clinical isolates of Haemophilus influenzae and Moraxella catarrhalis collected during 1999-2000 from 13 countries. (2001) (29)
Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa. (1997) (29)
In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (29)
Expression of the mef(E) Gene Encoding the Macrolide Efflux Pump Protein Increases in Streptococcus pneumoniae with Increasing Resistance to Macrolides (2005) (29)
Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa (1994) (29)
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. (2005) (28)
In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species (1997) (28)
The use of macrolides in treatment of upper respiratory tract infections (2005) (28)
Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends. (2015) (28)
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. (2011) (28)
Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential (2017) (27)
In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. (1992) (27)
Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004. (2006) (27)
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. (2009) (26)
Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals. (2012) (26)
Antibiotics and collateral damage. (2004) (26)
Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000 (2002) (26)
Scissors: A Potential Source of Nosocomial Infection (2002) (26)
Pyuria in institutionalized elderly subjects. (1991) (26)
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins? (2001) (26)
Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. (2011) (26)
Screening of Stool Samples for Identification of Vancomycin-Resistant Enterococcus Isolates Should Include the Methyl-α-dGlucopyranoside Test To Differentiate Nonmotile Enterococcus gallinarum from E. faecium (1998) (25)
Synergy of an Investigational Glycopeptide, LY333328, with Once-Daily Gentamicin against Vancomycin-ResistantEnterococcus faecium in a Multiple-Dose, In Vitro Pharmacodynamic Model (1999) (25)
Clinical implications of macrolide resistance in community-acquired respiratory tract infections (2006) (25)
Influence of Human Serum on Pharmacodynamic Properties of an Investigational Glycopeptide, LY333328, and Comparator Agents against Staphylococcus aureus (1998) (25)
In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. (1994) (24)
Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary (2005) (24)
Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains (1997) (24)
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. (2008) (24)
Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. (2010) (24)
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. (2008) (24)
Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016. (2018) (24)
Influence of human urine on the in vitro activity and postantibiotic effect of ciprofloxacin against Escherichia coli. (1991) (24)
Antibiotic Susceptibilities Among Recent Clinical Isolates of Haemophilus influenzae and Moraxella catarrhalis from Fifteen Countries (2001) (24)
Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15. (2018) (23)
Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. (2010) (23)
Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011 (2015) (23)
In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (23)
In vitro postantibiotic effects following multiple exposures of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli in pooled human cerebrospinal fluid and Mueller-Hinton broth (1993) (23)
Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals (1999) (23)
Evaluation of an Algorithmic Approach in Comparison with the Illumigene Assay for Laboratory Diagnosis of Clostridium difficile Infection (2013) (23)
In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011. (2014) (22)
Designing Fluoroquinolone Breakpoints for Streptococcus pneumoniae by Using Genetics instead of Pharmacokinetics-Pharmacodynamics (2004) (22)
Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens. (2001) (22)
Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study. (2019) (21)
Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study (2018) (21)
In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012. (2014) (21)
Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. (2004) (21)
Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus (1991) (21)
Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. (2011) (21)
Wound sterilization: CO2 laser versus iodine. (1989) (21)
Molecular Epidemiology and Prevalence of Macrolide Efflux Genes mef(A) and mef(E) in Streptococcus pneumoniae Obtained in Canada from 1997 to 2002 (2005) (20)
Performance of the ImmunoCard STAT! E. coli O157:H7 Test for Detection of Escherichia coli O157:H7 in Stools (2000) (20)
Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine. (2012) (20)
Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007. (2009) (19)
Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. (2000) (19)
Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16. (2019) (19)
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. (1994) (19)
Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003. (2005) (19)
The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance. (1993) (19)
Comparison of agar disk diffusion, microdilution broth, and agar dilution for testing antimicrobial susceptibility of coagulase-negative staphylococci (1987) (18)
Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents (1998) (18)
Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. (2019) (18)
In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16 (2018) (18)
Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. (2002) (18)
Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection (1988) (18)
Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study. (2003) (17)
In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study. (2004) (17)
Ketolides in the treatment of respiratory infections (2002) (16)
Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole (1996) (16)
Characterization of MRSA in Canada from 2007 to 2016. (2019) (16)
Trending Eight Years of In Vitro Activity of Ertapenem and Comparators Against Escherichia Coli from Intra-abdominal Infections in North America—SMART 2002-2009 (2011) (15)
Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016 (2018) (15)
Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. (2006) (15)
Effect of subinhibitory concentrations of Ciprofloxacin and gentamicin on the adherence of Pseudomonas aeruginosa to Vero cells and voided uroepithelial cells. (1993) (15)
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program (2015) (15)
The use of macrolides in treatment of upper respiratory tract infections (2006) (14)
Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16. (2019) (14)
Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime. (1994) (14)
Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15. (2018) (14)
Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results from CANWARD 2007. (2009) (13)
Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study. (2014) (13)
Mecillinam Activity Compared to Ampicillin, Trimethoprim/Sulfamethoxazole, Ciprofloxacin and Nitrofurantoin against Urinary Tract Isolates of Gram-Negative Bacilli (1998) (13)
Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012. (2015) (13)
Introduction to the CANWARD Study (2007-2009). (2011) (12)
Surveillance of susceptibility testing methodologies for Haemophilus influenzae in Canada, including evaluation of disk diffusion test (1994) (12)
Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates. (2014) (12)
Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group. (1995) (12)
Klebsiellapneumoniae isolates possessing KPC beta-lactamase in Israel, Puerto Rico, Colombia and Greece. (2009) (11)
Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008–2009) (2012) (11)
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. (2007) (11)
Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens. (2007) (10)
Introduction to the CANWARD study (2007–11). (2013) (10)
Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model. (2014) (10)
In vitro activity of lomefloxacin against Chlamydia trachomatis, Neisseria gonorrhoeae, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum. (1989) (10)
Brief reports Presence of ROB-1 -lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae (2000) (10)
Activity of Ceftolozane-Tazobactam and Comparators against Pseudomonas aeruginosa from Patients in Different Risk Strata -- SMART United States 2016-2017. (2020) (10)
Characterization of the inoculum effect with Haemophilus influenzae and beta-lactams. (1999) (9)
In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species. (1997) (9)
Comparison of CO2 Generation (BACTEC) and Viable-Count Methods To Determine the Postantibiotic Effect of Antimycobacterial Agents against Mycobacterium avium Complex (1998) (9)
positive clinical isolates obtained from patients in Canadian hospitals as (2014) (9)
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011. (2012) (9)
Positive Bactec resin cultures do not influence antimicrobial selection. (1990) (9)
In-vitro activity of a new penem FCE 22101. (1989) (9)
Antibiotic susceptibility profiles of European Bacteroides fragilis with reduced carbapenem susceptibility. (2010) (9)
Antimicrobial activity of subinhibitory concentrations of ciprofloxacin against Pseudomonas aeruginosa as determined by the killing curve method and the postantibiotic effect. (1992) (8)
Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables. (2008) (8)
In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012. (2014) (8)
In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). (2009) (8)
Comparative In Vitro Activity of Telithromycin and β-Lactam Antimicrobials Against Bacterial Pathogens from Community-Acquired Respiratory Tract Infections: Data from the First Year of PROTEKT (1999-2000) (2003) (8)
Low prevalence of VRE gastrointestinal colonization of hospitalized patients in Manitoba tertiary care and community hospitals. (2000) (8)
GSK2251052, a Novel Boron-containing Protein Synthesis Inhibitor, with Comparative in vitro Activity against Pseudomonas aeruginosa from a Global Population (2011) (7)
Clinical And Bacteriological Impact Of Clarithromycin In Streptococcal Pharyngitis: Findings From A Meta-Analysis Of Clinical Trials (2019) (7)
Fluoroquinolone resistance in Escherichia coli isolated from patients attending Canadian hospitals is associated with the ST131 clone. (2011) (7)
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species. (1998) (7)
Prevalence and Characterization of Macrolide Resistance in Clinical Isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America (2002) (7)
Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model. (2008) (7)
Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012 (2015) (7)
In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application. (1993) (6)
Comparative in vitro activity of quinolones. (1989) (6)
Comparative In Vitro Potency of Gemifloxacin and Fluoroquinolones Against Recent European Clinical Isolates from a Global Surveillance Study (2001) (6)
Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae. (2006) (6)
Phosphoenolpyruvate carboxylase of Thiobacillus thioparus. I. General properties. (1975) (6)
The accumulation of fluoroquinolones in Staphylococcus aureus during the postantibiotic effect. (1994) (5)
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model. (2009) (5)
Change in antimicrobial susceptibility of Escherichia coli urinary tract isolates at a single institution over a period of 10 years. (2012) (5)
In Vitro Activity of Retapamulin (SB-275833), a Novel Topical Antimicrobial, against 3721 Gram-Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) From 17 Sites in North America (2005) (5)
Stability of Fluoroquinolone Resistance in Streptococcus pneumoniae Clinical Isolates and Laboratory-Derived Mutants (2005) (5)
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model. (2012) (5)
Enprofylline disposition in the presence and absence of amoxycillin or erythromycin. (1987) (5)
Reproducibility of the in-vitro postantibiotic effect of fluoroquinolones against Staphylococcus aureus. (1990) (5)
In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 16.5%) application (1993) (5)
Comparative In Vitro Surveillance of Amoxicillin-Clavulanic Acid and Four Oral Comparators Against 21,232 Clinical Isolates from Europe (2003) (5)
Impact of carbon dioxide on the susceptibility of key respiratory tract pathogens to telithromycin and azithromycin. (2005) (5)
Urine screening with the MS-2 (1983) (5)
The use of ketolides in treatment of upper respiratory tract infections (2004) (4)
Increasing Genetic Relatedness of Ciprofloxacin-Resistant Streptococcus pneumoniae Isolated in Canada from 1997 to 2005 (2008) (4)
Vancomycin-resistant enterococci (VRE) colonization of high-risk patients in tertiary care Canadian hospitals. Canadian VRE Surveillance Group. (1999) (4)
Ceftolozane/Tazobactam: A Novel Cephalosporin/b-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli George G. ZhanelPhillip ChungHeather AdamSheryl ZelenitskyAndrew Denisuik • Frank SchweizerPhilippe R. S. Lagace ´-WiensEthan RubinsteinAlfred S. GinAndrew (2014) (4)
In Vitro Activity of MX-2401 a Novel Lipopeptide Against Multi-Drug Resistant (MDR) Staphylococcus aureus (SA) (2008) (4)
Aeromonas as a stool pathogen (1983) (3)
Retapamulin (SB-275833), a Novel Pleuromutilin - a Multi-center Global Surveillance of Activity Against 3,797 Beta and Alpha Hemolytic Streptococci Isolated from Skin and Skin Structure Infections (SSSIs) (2005) (3)
#P 811 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms (2004) (3)
Pharmacokinetic Disposition of Loracarbef in Healthy Young Men and Women at Steady State (1994) (3)
UrineScreening withtheMS-2 (1983) (3)
A-101 Microdilution Testing Methodology for Tigecycline: Addition of A Biocatalytic Oxygen- Reducing Agent May Be Required in The Absence of Fresh Media (2004) (3)
In vitro activities of ceftobiprole and doripenem tested against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens isolated from patients in Canadian hospitals in 2007. (2009) (3)
Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model. (2006) (3)
Ciprofloxacin or imipenem use correlates with resistance in Pseudomonas aeruginosa. (1998) (3)
Prevalence and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated in Canadian hospitals: Results from CANWARD 2007 (2009) (3)
Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates. (2006) (3)
Mutant Prevention Concentrations of Doripenem and Meropenem Alone and in Combination with Colistin (Polymyxin E), Levofloxacin and Tobramycin in Pseudomonas aeruginosa (2009) (3)
Evolving patterns of resistance to respiratory pathogens in Canada. (1999) (3)
Once versus Thrice Daily Tobramycin Alone and in Combination with Ceftazidime, Ciprofloxacin and Imipenem in an in vitro Pharmacodynamic Model (1997) (3)
Antimicrobial-Resistant Streptococcus pneumoniae in Canadian Hospitals: Results from the 2007 CANWARD Study (2009) (3)
Correction to: Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations (2018) (2)
Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America. (2002) (2)
Analysis of 1560 inpatient and outpatient Escherichia coli isolates from across Canada - Results from the CANWARD 2007 study (2009) (2)
Antimicrobial susceptibility of 6685 organisms isolated from Canadian hospitals: CANWARD 2007. (2009) (2)
Characterization of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: Results of the CANWARD 2007 study (2009) (2)
Retapamulin (SB-275833), A Novel Topical Pleuromutilin, Is Active Against Community Associated Methicillin- and Mupirocin-Resistant S. aureus Isolates From Uncomplicated Skin And Skin Structure Infections (SSSIs) (2005) (2)
Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia (2006) (2)
Glutamate uptake in Thiobacillus novellus. (1977) (2)
Central Line-Associated Blood Stream Infection (CLABSI) (2014) (2)
Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria. (1989) (2)
The North American Component (USA, Canada) of an International Comparative MIC Trial Monitoring Ofloxacin Resistance (1993) (1)
R2165 In vitro activity of tigecycline and commonly-used antimicrobials against clinical isolates collected from 2004 to 2006 in Spain and Portugal (2007) (1)
Clarithromycin versus Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials (2021) (1)
1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017 (2018) (1)
A Global Surveillance to Determine Tigecycline’s in vitro Activity against Multi-Drug Resistant Enterobacteriaceae (2005) (1)
Determination ofAntimicrobial Susceptibilities ofCanadian Isolates of Haemophilus influenzae andCharacterization ofTheir 1-Lactamases (1994) (1)
P 802 Global In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program (2004) (1)
Effect ofPooled HumanCerebrospinal Fluid on thePostantibiotic Effects ofCefotaxime, Ciprofloxacin, andGentamicin against Escherichia coli (1992) (1)
Value of routine procurement of Isolator in addition to BacT/Alert blood cultures in febrile neutropenic patients with acute myeloid leukemia (1998) (1)
Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010). (2012) (1)
Comparative antifungal activity of cilofungin (LY121019) against Candida species, including evaluation of susceptibility testing method. (1992) (1)
Global Susceptibility Trends and Extended Spectrum Beta-lactamase (ESBL) Rates Among Proteus mirabilis : Results of the SMART 2010-2014 Analysis (2015) (1)
Tigecycline and Comparators Against S. pneumoniae: A Global Study (2008) (0)
P2048 Comparison of in vitro activity of tigecycline against pathogens from intensive care patients in Europe –T.E.S.T. Program 2006 (2007) (0)
Activity of Tigecycline and comparators against aerobic intra-abdominal pathogens in Asia/Pacific: 2004 - 2011 (2012) (0)
Short communication Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae (2006) (0)
R2162 Tigecycline antibacterial activity in current (2004–2006) European population – An Age Population Analysis – T.E.S.T. Program 2006 (2007) (0)
P744 Changes in United States regional variations in penicillin-resistant rates of Streptococcus pneumoniae, 1999 to 2006 (2007) (0)
412In vitro Activity of Key Antimicrobial Agents Against Bacterial Isolates From Intra-abdominal (IAI) and Skin and Wound (SW) Infections: Europe 2004-2013 (2014) (0)
421Activity of Tigecycline and Comparators Against Lower Respiratory Tract (LRT) Isolates of from North America and Europe: 2009-2013. (2014) (0)
An Asia/Pacific Rim Perspective of Enterobacteriaceae Multi-drug Resistant (MDR) Isolates Against Tigecycline (2008) (0)
The In Vitro Activity of Tigecycline and 10 Comparators in a Global Population - T.E.S.T. Program 2006 (2006) (0)
P67 Antimicrobial resistance in pathogens isolated from Canadian hospital clinics (C), emergency rooms (ER), medical/surgical wards (W) and intensive care units (ICU): results of the CANWARD 2008 study (2009) (0)
difficile Infection Laboratory Diagnosis of Clostridium Comparison with the Illumigene Assay for Evaluation of an Algorithmic Approach in (2014) (0)
P1685 In vitro activity of tigecycline and 10 common therapeutic agents against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus species – Global Data, 2004 – 2006 (2007) (0)
P2053 Evaluation of in vitro activity of tigecycline and ten comparators against methicillin-resistant Staphylococcus aureus from 34 countries: TEST Program 2004–2006 (2007) (0)
Tigecycline and Comparators Against Extended Spectrum Beta-Lactamase (ESBL) Isolates Worldwide (2008) (0)
419Susceptibility trends for P. aeruginosa and A. baumannii from IAI in the USA: SMART 2009-2013 (2014) (0)
P57 Extended-spectrum p-lactamase-producing Escherichia coli (ESBL-EC) from patients in Canadian hospitals: preliminary results from CANWARD 2008 (2009) (0)
R2163 In vitro activity of tigecycline against common pathogens – Eastern European Data – T.E.S.T. Program 2006 (2007) (0)
Trends In Susceptibility Of P. Aeruginosa To Piperacillin-Tazobactam And Comparators 2004-2009 - Global T.E.S.T. Analysis (2011) (0)
Epidemiology and Detect Novel β-Lactamases: a Snapshot of ESBLs (2012) (0)
Infections (SSTI) Pathogens in Asia-Pacific -AWARE Surveillance Program 2012 (2013) (0)
P66 Escherichia coli isolates from Canadian hospitals – preliminary results of the CANWARD 2008 Study (2009) (0)
709. Activity of Key β-Lactam Agents Against Gram-Negative Bacilli From ICU Patients with Lower Respiratory Tract Infections, SMART United States 2015–2017 (2018) (0)
Accuracy in determining telithromycin MIC values against Streptococcus pneumoniae: Haemophilus influenzae and Streptococcus pyogenes: Etest vs. Broth Microdilution (2003) (0)
Gram Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) and Collected from Sites in the United States are Highly Susceptible to Retapamulin (SB275833), a Novel Topical Antimicrobial (2005) (0)
P51 Trends in ESBL-production and susceptibility for K. pneumoniae from intra-abdominal infections in Southeast Asia: SMART 2008–2011 (2013) (0)
Worldwide Prevalence of Macrolide Resistance Genotypes among Streptococcus pneumoniae from 2004 to 2008 (2009) (0)
Molecular characterization of beta-lactamases of Enterobacteriaceae with ertapenem MICS greater than 0.25, and impact of new CLSI carbapenem breakpoints (2011) (0)
Determining the Anti-bacterial Activity of Tigecycline and 10 Comparators Worldwide (2005) (0)
Activity of Doripenem vs. Comparator Carbapenems vs. Prevalent Canadian Hospital Pathogens: CANWARD 2007 (2008) (0)
Tigecycline Activity in Current (2008) Global Population - An Age Analysis: (2008) (0)
In Vitro Activity of Tigecycline against Commonly Isolated Pathogens of Skin and Skin Structure Infections in Latin America – TEST 2011-2014 (2015) (0)
Introduction to CANWARD 2007 (2009) (0)
Tissue Infections in Latin America -AWARE Surveillance 2012 (2013) (0)
Comparative Evaluation of Tigecycline and other Antimicrobials in the United States Against Multi-drug Resistant (MDR) Staphylococcus aureus (2008) (0)
P2050 Antimicrobial susceptibility of 2,537 bacteraemia causative pathogens: Tigecycline Evaluation Surveillance Trial (TEST) in Europe, 2004–2006 (2007) (0)
Oral Antibiotic In Vitro Activity In Sinusitis - United States Test Data 2004-2009 (2011) (0)
R2159 A survey of multi-drug resistance clinical pathogens in Turkey – T.E.S.T. Program 2006 (2007) (0)
Resistance Trends ( SMART ) Study for Monitoring Antimicrobial Infections in Europe : Results of the 2008 Hospital-Associated Intra-Abdominal-Lactamases in Community-and β with Extended-Spectrum pneumoniae Klebsiella and Escherichia coli of Incidence and Antimicrobial Susceptibility (2010) (0)
Resistance Trends ( SMART ) Program , 2007 the Study for Monitoring Antimicrobial fromBacilli in the Asia-Pacific Region : Data-Lactamase-Producing Gram-Negative β Extended-Spectrum-Emergence of High Levels of (2009) (0)
, the 16 S rRNA Gene Conformation Polymorphism Analysis of Single-Strand − Fluorescence-Based PCR Positive Blood Cultures by Rapid Identification of Bacteria from (2000) (0)
254In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013 (2014) (0)
P2 Pharmacodynamic (PD) activity of ceftobiprole (Cefto) compared to vancomycin (Vanco) vs. methicillin-resistant Staphylococcus aureus, vancomycin intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus using an in vitro model (2009) (0)
Bacteremic Fluoroquinolone Resistant Pseudomonas aeruginosa . A Global in vitro comparative analysis 2004-2008 (2009) (0)
Antibiotic Resistance in Lower Respiratory Tract Infection (LRTI) Pathogens in 2007, a 12-Hospital Canadian Perspective: The CANWARD Study (2008) (0)
Recent Surveillance Study of 2,901 Gram-Positive Isolates Associated with Skin and Skin Structure Infections (SSSIs) in the United States Demonstrates Excellent Activity of Retapamulin (SB275833), a Novel Topical Antimicrobial (2005) (0)
Comparative Analysis of Tigecycline in South America from 2004-2007 (2007) (0)
Tigecycline In Vitro Activity Against Often Difficult To Treat Pathogens From Centers In Asia/Pacific Rim - T.E.S.T. Program 2006 (2006) (0)
Diagnostic Microbiology and Infectious Disease (2014) (0)
Evaluation of Multidrug Resistant (MDR) Isolates Against Tigecycline: A Canadian Perspective (2008) (0)
In Vitro Activity of Tigecycline Against Staphylococcus aureus with Reduced Susceptibility to Vancomycin. A Global Analysis 2004-2009 (2009) (0)
In Vitro Activity of Colistin (Polymyxin E) Versus 2541 Pseudomonas aeruginosa Clinical Isolates Obtained from Patients in Canadian Hospitals: Results of the CANWARD Study, 2008-2014 (2015) (0)
P2049 In vitro activity of tigecycline against pathogens isolated from cerebrospinalfiuid –T.E.S.T. Program 2006 (2007) (0)
Laboratory diagnosis of chancroid. (1988) (0)
In Vitro Activity Of Tigecycline And Comparators Against Carbapenem-Resistant Enterobacteriaceae (CRE) From Respiratory Sources - TEST Data 2004-2010 (2012) (0)
2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017 (2018) (0)
Corrigendum to: Clarithromycin versus Amoxicillin alone or with Clavulanate in Acute Maxillary Sinusitis: A Meta-analysis of Clinical Trials (2021) (0)
#P 807 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against Gram-positive and Gram-negative Pathogens in Asia (2004) (0)
Multi-Drug Resistant (MDR) S. aureus Against Tigecycline and Comparators: A Global Evaluation (2008) (0)
In vitro activity of Tigecycline against molecularly defined Carbapenemase producing Acinetobacter baumannii (2010) (0)
Request for resin bottle guidelines (1988) (0)
P52 ESBL-production in Escherichia coli from urinary tract infections in Asia/Pacific (2013) (0)
R2161 In vitro activity of tigecycline in an outpatient vs. inpatient Western European population (2007) (0)
#P 441 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States (2004) (0)
P2051 Antibacterial activity of tigecycline against H. influenzae and S. pneumoniae (2004–06) Global Population –T.E.S.T. Program, 2006 (2007) (0)
P49 Streptococcus pneumoniae in Canadian hospitals: demographics, prevalence and antibiotic susceptibility testing results obtained during 2007 and 2008 Canadian Ward Surveillance Study (CANWARD) (2009) (0)
In Vitro Susceptibility Profiles of Klebsiella spp. Isolated from ICU and non-ICU Wards in North and Latin America (TEST Program 2012-2016) (2017) (0)
P1684 Tigecycline in vitro activity against often difficult to treat European pathogens (2007) (0)
Meropenem Resistant Klebsiella Pneumoniae In The USA: Data From T.E.S.T. 2009 (2011) (0)
The Use of Ketolides in Treatment of Upper Respiratory Tract Infections. (2004) (0)
Grepafloxacin Activity Against 3000 Canadian Respiratory Tract Pathogens (1999) (0)
Susceptibility Of Pathogens Isolated Fromcommunity-Acquired Pneumoniae (CAP) Sources To Tigecycline (T.E.S.T. 2004 - 2009) (2011) (0)
Surveillance of Antimicrobial Activity in Acinetobacter Species and Pseudomonas aeruginosa in the United States and Canada - T.E.S.T. Program 2004 - 2007 (2008) (0)
P1121 Patterns of susceptibility of Gram-negatives/positives isolated in the United Kingdom and Ireland (2007) (0)
In Vitro Activity of Tigecycline and 13 Comparators against Pathogens from a Global Population of Intensive Care Patients in 2007 (2007) (0)
411Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-Abdominal Infections in Pediatric Patients in the U.S. – SMART 2010-2013 (2014) (0)
In vitro activity of Tigecycline and comparators against multidrug resistant Acinetobacter species in Asia: 2004 - 2011 (2012) (0)
413In Vitro Activity of Tigecycline against Commonly-Isolated Pathogens of Skin and Skin Structure Infections in the United States – TEST 2011-2013 (2014) (0)
Abstracts cont. (2005) (0)
In Vitro Activity of Gemifloxacin Against Multiple-drug-resistant Strains of Streptococcus pneumoniae Isolated From 42 Countries in North America, Latin America, Europe, Asia, South Pacific and Africa/Middle East (2000) (0)
Ceftaroline (2018) (0)
Use of Intravenous Ciprofloxacin in a Canadian Medical Centre (1999) (0)
P2047 Tigecycline Evaluation Surveillance Trial (T.E.S.T.)–United States in vitro antibacterial activity against selected species of Enterococcus spp. (2007) (0)
Evaluation of 11 Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program (2008) (0)
DDDT_A_205820 3551..3558 (2019) (0)
Ceftobiprole (2020) (0)
Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel (cid:1) -Lactamases: a Snapshot of Extended-Spectrum (cid:1) -Lactamases throughout the World (2012) (0)
421Activity of Tigecycline and Comparators Against Lower Respiratory Tract (LRT) Isolates of Enterobacteriaceae from North America and Europe: 2009-2013 (2014) (0)
Antibiogram Profiles For Extended-Spectrum Beta-Lactamase Producing Respiratory Pathogens: E. Coli, K. Oxytoca, And K. Pneumoniae - TEST Data 2006-2010 (2012) (0)
418Antimicrobial Profile of Enterobacteriaceae from North America from 2013 (2014) (0)
Trends in Susceptibility for Escherichia coli from Intra-abdominal Infections in Three European (2012) (0)
Tigecycline Susceptibility Trends Among Pathogens Isolated from Complicated Skin and Soft-Tissue Infections in North and Latin America: 2012–2016 (2017) (0)
Results Evaluating Multi-Drug Resistant Acinetobacter baumannii in Critical Care Units (2011) (0)
658: CEFTOLOZANE-TAZOBACTAM AND IMIPENEM-RELEBACTAM IN VITRO ACTIVITY VS. MDR P AERUGINOSA FROM U.S. ICUS (2019) (0)
A worldwide surveillance program studying the In Vitro Activity of Tigecycline and 10 common therapeutic agents against methicillin-resistant Staphylococcus aureus and Vancomycinresistant Enterococcus species from 2004–2009 (2010) (0)
Methicillin- and Mupirocin-Resistance in Community-Associated S. aureus Obtained from Uncomplicated Skin and Skin Structure Infections (SSSIs) in the United States in 2004-2005; Retapamulin Surveillance Study. (2005) (0)
Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016 (2018) (0)
A Global Surveillance Program to Determine the In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter spp. (2005) (0)
R2160 Tigecycline antibacterial activity in current (2004–2006) global population – A Gender Population Analysis – T.E.S.T. Program 2006 (2007) (0)
Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013 (2015) (0)
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. (2002) (0)
The in Vitro Activity of Tigecycline and Antimicrobial Cross-Resistance Against Enterobacteriaceae Worldwide (2008) (0)
Evaluation of Tigecycline in the United States Against Antimicrobial Resistant Acinetobacter (2008) (0)
Tigecycline In Vitro Activity Against Vancomycin-Resistant Enterococci And Methicillin-Resistant Staphylococcus Aureus In Critical Care Units (2012) (0)
P2054 Impact of different FDA and EU breakpoints on bacterial susceptibility patterns-Analysis of data from the T.E.S.T. Program (2007) (0)
In Vitro Potency of Tigecycline Against Pathogens from Most Common Body Sites: A Study in Asia/Pacific Rim (2008) (0)
R2157 Antimicrobial susceptibility of 2,254 isolates from different body sites: Tigecycline Evaluation Surveillance Trial (TEST) in South America, 2004–2006 (2007) (0)
THE UNIVERSITY OF MANITOBA DEPARTMENT OF INTERNAL MEDICINE POSTGRADUATE EDUCATION PROGRAM RESIDENT RESEARCH DAY (2011) (0)
P60 Emergence of carbapenem reduced susceptible (CRS) E. coli (EC) and K. pneumoniae (KP) in Canadian hospitals: results from CANWARD 2007 and 2008 (2009) (0)
In Vitro Activity of Tigecycline Against 23,125 Pathogens Isolated from Common Body Sites and Tissues in North America (2006) (0)
P93 Evaluation of the activity of ceftobiprole and doripenem against common clinical pathogens obtained from Canadian hospital wards using Etest methodology (2009) (0)
An Evaluation of Tigecycline and Comparators in Asia/Pacific Rim for Often Difficult to Treat Pathogens (2008) (0)
Extended-spectrum beta-lactamase positive rates for E. coli, K. pneumoniae, and K. oxytoca in 10 Asian countries - TEST program from 2004-2011 (2012) (0)
In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 (2017) (0)
P2052 Variable resistance patterns among tigecycline and 10 comparators against multidrug-resistant Acinetobacter from the T.E.S.T. Program (2007) (0)
Tigecycline Comparison with Minocycline Resistance Pathogens. A Worldwide Perspective (2008) (0)
Comparison of susceptibility trends of Escherichia coli from intra-abdominal infections in high- vs. low-to-middle-income countries: SMART 2008-2012 (2014) (0)
Evaluation of Tigecycline and Other Antimicrobials in Latin America Against Multi-drug Resistant (MDR) Staphylococcus aureus (2008) (0)
417Comparison of ESBL rates and susceptibility of E. coli from IAI in the USA, Canada, and Mexico 2009-2013 (2014) (0)
A Global Evaluation of Vancomycin Resistant Enterococci (VRE) Against Tigecycline: The T.E.S.T. Program (2008) (0)
Monitoring Of Tigecycline In Vitro Activity In Nosocomial Pneumonia Isolates From North American Intensive Care Units - Test Data 2004-2009 (2011) (0)
Bacterial Resistance Patterns of Isolates from Various Body Sites: The European T.E.S.T. Program (2008) (0)
Resistance Patterns of Methicillin- and Mupirocin-resistant S. aureus from Uncomplicated Skin and Skin Structure Infections (SSSIs) in the United States from March 2004-March 2005; Retapamulin Surveillance Study (2005) (0)
#P-657 Tigecycline in vitro Activity against Staphylococcus aureus and Enterococcus strains Resistant To Other Drugs In The T.E.S.T. Program - United States, 2004 - 2005 (2005) (0)
Efficacy of Tigecycline Against Worldwide Levofloxacin-Resistant Pathogens (2008) (0)
Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity Against Nosocomial Pathogens in South America, 2004-2006 (2006) (0)
Invasive Streptococcus pneumoniae serotypes associated with in-patient and out-patient isolates from the United States (2010) (0)
Tigecycline Activity in Gram-Positive Pathogens in the First Four Years - TEST Data from the United States and Canada, 2004 - 2007 (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Daryl J. Hoban?

Daryl J. Hoban is affiliated with the following schools:

Daryl J. Hoban's Academic­Influence.com Rankings

Daryl J. Hoban's Degrees

Why Is Daryl J. Hoban Influential?

Daryl J. Hoban's Published Works

Published Works

What Schools Are Affiliated With Daryl J. Hoban?

Daryl J. Hoban's AcademicInfluence.com Rankings